To further investigate the efficacies of adjuvant EGFR TKIs treatment in EGFR-mutant NSCLC patients, propensity-score analysis was applied to match the patients in the two groups, using clinicopathologic covariates. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.